First-generation cephalosporins for the treatment of complicated upper urinary tract infection in adults: A systematic literature review

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Cytomegalovirus infection among people living with HIV in Sweden: Case profiles, treatment strategies and patient outcomes at Karolinska University Hospital 2010–2020

“…However, close monitoring for persistent CMV viraemia in PLWH with poor immune reconstitution despite ART treatment may be an important practice in the management of this patient group. Indeed, while our results align with previous research indicating that CMV viraemia does not independently predict disease progression or mortality in patients with advanced HIV initiating ART [11], a recent meta-analysis has highlighted the potential advantages of pre-emptive therapy in preventing CMV EOD in PLWH [24].…”

Guía de práctica clínica para la infección de vías urinarias complicada

“…Los comparadores fueron cefamicinas, cefalosporinas de tercera generación y quinolonas. Algunos estudios reportaron un mayor riesgo de falla microbiológica con cefalosporinas de primera generación, sin embargo, se encontró que la eficacia clínica fue similar a los comparadores, sin diferencia en los desenlaces de cura clínica, recaída y reinfección 37 .…”

Consenso de expertos para el tratamiento antimicrobiano de las infecciones causadas por bacilos gram negativos multirresistentes en pacientes adultos

“…Las opciones preferidas de tratamiento de pielonefritis por Pseudomonas aeruginosa con resistencia difícil de tratar (DTR) son ceftolozano-tazobactam, ceftazidima-avibactam, imipenemcilastatina-relebactam y cefiderocol (los dos últimos, actualmente sin registro INVIMA). Ensayos controlados aleatorizados muestran la no inferioridad de estos agentes frente a los agentes comparadores habituales 19,[52][53][54] sensibilidad in vitro, el uso de ceftolozano/tazobactam como primera alternativa para reservar otras opciones en casos de resistencia y disminuir la presión selectiva.…”